|
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Blocking Tumor Necrosis Factor in Ankylosing Spondylitis conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Blocking Tumor Necrosis Factor in Ankylosing Spondylitis Clinical research trials and Blocking Tumor Necrosis Factor in Ankylosing Spondylitis health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Blocking Tumor Necrosis Factor in Ankylosing Spondylitis. Blocking Tumor Necrosis Factor in Ankylosing Spondylitis Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Blocking Tumor Necrosis Factor in Ankylosing Spondylitis clinical trial. Human subjects often get the best healthcare possible for their Blocking Tumor Necrosis Factor in Ankylosing Spondylitis condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Blocking Tumor Necrosis Factor in Ankylosing Spondylitis  Blocking Tumor Necrosis Factor in Ankylosing Spondylitis
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis
For Condition: Spondylitis, Ankylosing
Status: Completed
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: The Division of Rheumatology at University of California San Francisco is conducting a research study on the treatment of ankylosing spondylitis (AS) with a new therapy currently used for people with other forms of arthritis. The drug, called Enbrel (or etanercept), is a protein that is given twice weekly by injection underneath the skin. It blocks the action of tumor necrosis factor-alpha (TNF-alpha), a substance that may be involved in AS, rheumatoid arthritis, and other inflammatory conditions. We will randomly assign patients to receive either the drug or a placebo (inactive treatment) for 4 months. The results we will monitor include morning stiffness, spinal mobility, activities of daily life, and safety of the drug.
Details: In this Phase II clinical trial we will use tumor necrosis factor receptor p75 fusion protein (TNFR:Fc, or etanercept) to treat patients with ankylosing spondylitis (AS). TNFR:Fc is an antagonist of tumor necrosis factor (TNF), a cytokine that researchers have shown to play a possible role in disease pathogenesis of ankylosing spondylitis, rheumatoid arthritis, and vasculitis, as well as other inflammatory conditions. TNFR:Fc consists of two molecules of the extracellular portion of the p75 receptor, each consisting of 235 amino acids. The two receptors are fused to the Fc portion of human IgG1, which consists of 232 amino acids. The gene fragments encoding the truncated TNFR and the Fc portion of human IgG1 are expressed in a Chinese hamster ovary cell line. Recent observations from animal and human studies suggest that tumor necrosis factor-alpha (TNF-alpha) may play a role in disease activity in AS and other seronegative spondyloarthropathies. This study aims to test the efficacy of TNFR:Fc used in conjunction with standard medications in the treatment of AS. We will give patients either 25mg of TNFR:Fc or placebo subcutaneously twice a week for 4 months. Outcome measures will include measures of function, pain, morning stiffness, patient global assessment, and swollen joint count, as well as safety measures.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/80 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Diagnosis of Ankylosing spondylitis - Acceptable stable treatments during study: oral glucocorticoids (less than or equal to 10 mg/d) and/or NSAIDs at recommended doses and/or one of the following options: methotrexate (less than or equal to 20.0 mg/week); sulfasalazine (less than or equal to 3 grams/d); azathioprine (less than or equal to 2 mg/kg/d); methotrexate and sulfasalazine combination at doses listed above; 6-mercaptopurine (less than or equal to 1.5 mg/kg/d) Exclusion Criteria: - Diagnosis of psoriatic arthritis, inflammatory bowel disease, reactive arthritis, or Behýet disease - Significant medical problems, such as diabetes mellitus - History of active or recurrent infections - Complete ankylosis of the entire spine
Total Enrollment: 42
Location and Contact Information:
Overall Study Official:
JohnDavis, Principal Investigator, UCSF Dept.of Medicine, Division of Rheumatology
UCSF-Clinical Trials Center
San Francisco, California, 94143-0792
United States
Additional Information:
Study ID Numbers: NIAMS-043; N01-AR-9-2244
Study Start Date: October 1999
Record last reviewed: February 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000433
Other Spondylitis, Ankylosing Studies:
1. Blocking Tumor Necrosis Factor in Ankylosing Spondylitis
Related Studies:
Other Spondylitis, Ankylosing Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis
|
|
|
|
|
|
|
|
